Patents Examined by Shannon A. Foley
  • Patent number: 11007263
    Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?I1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: May 18, 2021
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Douglas P. Gladue, Manuel V. Borca
  • Patent number: 10894081
    Abstract: The present disclosure relates to a foot-and-mouth disease virus vaccine composition, especially a recombinant bivalent vaccine composition against type O and type A foot-and-mouth disease viruses. The present disclosure further relates to a method for preparing the foot-and-mouth disease virus vaccine composition, and a use of the foot-and-mouth disease virus vaccine composition in preparing medicines for preventing and/or controlling foot-and-mouth disease in animals.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: January 19, 2021
    Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Weijun Cao, Hong Tian, Keshan Zhang, Dan Li, Ye Jin, Jianhong Guo, Jijun He, Xuepeng Cai, Xiangtao Liu
  • Patent number: 10858634
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10690669
    Abstract: Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 23, 2020
    Inventor: Shafiqul I. Chowdhury
  • Patent number: 10619169
    Abstract: The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site ORF70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 14, 2020
    Inventors: Alice Mundt, Andreas Gallei, Kristina Rehmet
  • Patent number: 10576142
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: March 3, 2020
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10407491
    Abstract: The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 10, 2019
    Assignee: The Texas A&M University System
    Inventors: Waithaka Mwangi, Surya Waghela, Luc Berghman
  • Patent number: 10279028
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 7, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 9975925
    Abstract: Novel influenza antigens, novel immunogenic or vaccine compositions, as well as uses of and methods for producing said antigens and compositions, are described.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: May 22, 2018
    Inventors: James Stevens, Ruben Donis, David Shore, Hongquan Wan, Ventzislav Bojidarov Vassilev
  • Patent number: 9212400
    Abstract: The present invention relates to methods for the detection of the presence of swine Torque Teno virus in a sample, for the detection of replication of swine Torque Teno virus in a sample, to Torque Teno virus (RT)-PCR primers and probes, and to diagnostic test kits for the detection of the presence and replication of swine Torque Teno virus in a sample.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: December 15, 2015
    Assignee: Intervet Inc.
    Inventors: Erwin van den Born, Vivian Cornelissen-Keijsers, Tuija Kekarainen, Joaquim Segalés, Laura Martinez-Guinó, Maria Ballester
  • Patent number: 8734808
    Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 27, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Patent number: 8168419
    Abstract: Petroleum reservoir souring, caused by microbially induced production of hydrogen sulfide and other sulfur compounds, and the attendant corrosion are remediated by isolating bacteriophage(s) specific for the problematic bacteria (target bacteria) and adding an effective amount of such bacteriophage(s) to water introduced into or resident in the reservoir to kill at least some of the target bacteria. Suitable virulent bacteriophage(s) may be indigenous to the water, located in surrounding areas, or taken from a known banked stock. Means of concentrating solutions of bacteriophage(s) are also disclosed.
    Type: Grant
    Filed: December 31, 2010
    Date of Patent: May 1, 2012
    Assignee: Phage Biocontrol Research, LLC
    Inventors: Douglas Baldwin, Neil S. Summer
  • Patent number: 7358060
    Abstract: The present invention provides a method for diagnosis, monitoring and prognosticating the disease course of gastrointestinal tumors, comprising determining the level of a cyclin dependent kinase inhibitor (CK1) in a sample and diagnosing the disease and/or recurrence of the disease or prognosticating the disease course from the level of said CK1 in the examined tumor cells. Furthermore the present invention provides a method for tailoring a suitable therapy for gastrointestinal tumors. Another aspect of the present invention are test kits for research and diagnostic purposes.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 15, 2008
    Assignee: MTM Laboratories, AG
    Inventors: Reinhard von Wasielewski, Michael Mengel, Rüdiger Ridder, Peter Martin
  • Patent number: 6887479
    Abstract: The present invention describes recombinant RV mutants comprising a combine mutation in two different parts of the viral genome, involving the P and the G genes. The mutations in the P gene preferably encompass residues 139 to 170, more preferably residue 139 to 149, most preferably residues 143-149. The mutation can be a substitution or deletion of one or more amino acids in the above region, as well as combinations of deletion and substitution.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 3, 2005
    Assignee: Akzo Nobel N.V.
    Inventor: Teshome Mebatsion
  • Patent number: 6869794
    Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: March 22, 2005
    Assignee: Crucell Holland, B.V.
    Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
  • Patent number: 6841158
    Abstract: Recombinant CELO virus or CELO virus DNA with a deletion at the right end of the viral genome that allows insertion of large pieces of foreign DNA. The virus is useful as a vaccine for animals, in particular birds, and for gene therapy and vaccine applications in humans. The virus can also be used for recombinant protein production.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: January 11, 2005
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthew Cotten, Anne-Isabelle Michou, Gerhard Christofori, Amelia Compagni
  • Patent number: 6583264
    Abstract: A potent and highly specific insecticidal toxin comprising 45 residues and three intramolecular disulfide bonds, as well as a method for selecting potent inhibitors of insect calcium channels.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: June 24, 2003
    Assignee: University of Connecticut
    Inventors: Glenn F. King, Xiu-hong Wang
  • Patent number: 6498019
    Abstract: This invention relates to a novel protein having a lecithin-cholesterol acyltransferase-like activity, etc. or its salt, a precursor protein of the protein or its salt, a partial peptide of the protein or its salt; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein, a pharmaceutical composition comprising the protein, the partial peptide or its salt; and an antibody to the protein or the partial peptide. The protein, the partial peptide or its salt, and the DNA are useful as an agent for treating or preventing arteriosclerosis, atherosclerosis, hyperlipidemia, hypercalorism, obesity or hypertriglyceridemia. The antibody can be used in assay of the protein, the partial peptide or its salt. The protein, the partial peptide or its salt is useful as a reagent for the screening for candidate medical compounds.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: December 24, 2002
    Assignee: Takeda Chemical Industries, Ltd.
    Inventor: Yoshio Taniyama
  • Patent number: 6416764
    Abstract: A vaccine comprises a non-cytopathogenic strain of bovine viral diarrhea virus, grown in a bovine derived cell line such as MDBK and killed, for example with &bgr;-propiolactone. The adjuvant is Quil A.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: July 9, 2002
    Assignee: Vericore Limited
    Inventors: John Christopher Howard, Michael Cyril Clarke, John Brownlie